CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

The objective of the registry is to create a cohort of adolescent subjects with AD to evaluate the long-term safety and effectiveness of AD treatments. Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of AD to support ongoing risk-benefit evaluation by drug manufacturers and regulators. Further, data collected will inform clinical decision making by patients and treating providers. This will be done through standardized data collection including validated instruments for patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

This provides an opportunity to evaluate other aspects of the disease and its treatment, including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and subject adherence.

Inclusion criteria

• To be eligible to participate in this registry, an individual must meet all the following criteria:

• Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare provider
• Is 10 - 15 years of age at the time of enrollment.
• Subject has initiated or is initiating an enrollment-eligible medication at the time of enrollment

Exclusion criteria

• An individual who meets any of the following criteria will be excluded from participation in the registry:

• Is participating or planning to participate in a blinded clinical trial for an AD drug.
• Is unwilling or unable to provide standing height measurements.